Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Endoscopic Sleeve Gastroplasty Versus Laparoscopic Sleeve Gastrectomy in Obese Subjects With NASH (TESLA-NASH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04060368
Recruitment Status : Recruiting
First Posted : August 19, 2019
Last Update Posted : September 30, 2020
Sponsor:
Information provided by (Responsible Party):
UECV, Instituto de Investigación Marqués de Valdecilla

Brief Summary:

The primary objectives of this study are to evaluate the effect of ESG with OverStitch® system (Apollo Endosurgery, Austin, TX, USA) compared to LSG on 1) histological improvement in NASH; 2) all-cause mortality and liver-related outcomes In obese subjects with non-alcoholic steatohepatitis (NASH).

Condition or disease: Non-alcoholic steatohepatitis (NASH) with or without fibrosis Intervention/treatment: ESG with OverStitch® system vs LSG


Condition or disease Intervention/treatment Phase
Non-alcoholic Steatohepatitis (NASH) Procedure: Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications Procedure: Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Experimental: Endoscopic Sleeve Gastroplasty with OverStitch® system + Lifestyle modifications Comparator: Laparoscopic Sleeve Gastrectomy + Lifestyle modifications
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: STudy to Evaluate the Efficacy and Safety of Endoscopic Sleeve Gastroplasty (ESG) Versus LAparoscopic Sleeve Gastrectomy (LSG) in Obese Subjects With Non-Alcoholic SteatoHepatitis (NASH)
Actual Study Start Date : June 1, 2020
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : June 1, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy

Arm Intervention/treatment
Experimental: ESG Stitch® system + Lifestyle modifications
Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).
Procedure: Endoscopic Sleeve Gastroplasty (ESG) with OverStitch® system + Lifestyle modifications
Endoscopic technique defined as a gastric restriction by means of continuous sutures of the entire gastric wall of the antrum and body, transmurally, in order to simulate a gastric sleeve, in the same way as sleeve gastrectomy surgery. Gastroplasty is performed using an endoscopic suture system (OverStitch, Apollo Endosurgery Inc., Austin, Texas, USA) inserted into a dual-channel endoscope (GIF-2T160, Olympus Medical Systems Corp., Tokyo, Japan).

Active Comparator: LSG + Lifestyle modifications
Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.
Procedure: Laparoscopic Sleeve Gastrectomy (LSG) + Lifestyle modifications
Minimally invasive surgical technique defined as a gastric restriction by means of an excision approximately 80% of the stomach along the greater curvature.




Primary Outcome Measures :
  1. Proportion of subjects undergoing ESG relative to LSG achieving resolution of NASH without worsening of fibrosis [ Time Frame: Measurement at 96 weeks ]
    To evaluate the effect of ESG compared to LSG on liver histology in obese subjects with NASH with or without fibrosis by assessing the following endpoint: The proportion of subjects undergoing ESG relative to LSG achieving NASH resolution without worsening of fibrosis. NASH resolution is defined as the disappearance of ballooning and the disappearance or persistence of minimal lobular inflammation (grade 0 or 1) The worsening of fibrosis is defined as the progression of at least one stage.

  2. Proportion of subjects undergoing ESG relative to LSG with cardiovascular and liver-related death events [ Time Frame: Measurement at 96 weeks ]
    To evaluate the effect of ESG compared to LSG on liver histology in obese subjects with NASH with fibrosis by assessing the following endpoint: The proportion of subjects undergoing ESG relative to LSG achieving improvement of liver fibrosis of at least one stage.


Secondary Outcome Measures :
  1. Proportion of subjects undergoing ESG relative to LSG achieving improvement in liver histology according to the NASH-CRN scoring [ Time Frame: Measurement at 96 weeks ]
    Percentage of patients with at least 1 point improvement

  2. Changes in the liver enzymes [ Time Frame: Measurement at 96 weeks ]
    ALT, AST, GGT, AP (U/L)

  3. Changes in lipid parameter [ Time Frame: Measurement at 96 weeks ]
    Cholesterol, LDL, HDL, Triglycerides (mg/dL)

  4. Changes in noninvasive markers of fibrosis and steatosis [ Time Frame: Measurement at 96 weeks ]
    Fatty Liver Index (FLI) (<30; 30-60; >60)

  5. Changes in noninvasive markers of fibrosis and steatosis [ Time Frame: Measurement at 96 weeks ]
    Hepatic steatosis index (HSI) (<30; 30-36; >36)

  6. Changes in noninvasive markers of fibrosis and steatosis [ Time Frame: Measurement at 96 weeks ]
    NAFLD fibrosis score (NFS) (<-1.455; -1.455-0.676; >0.676)

  7. Changes in noninvasive markers of fibrosis and steatosis [ Time Frame: Measurement at 96 weeks ]
    AST to Plateler ratio index (APRI) (<1, >1)

  8. Changes in noninvasive markers of fibrosis and steatosis [ Time Frame: Measurement at 96 weeks ]
    Fibrosis-4 (FIB-4) (<1.30; 1.30-2.67; >2.67)

  9. Changes in noninvasive markers of fibrosis and steatosis [ Time Frame: Measurement at 96 weeks ]
    Hepamet fibrosis score (HFS) (<0.12; 0.12-0.47; >0.47)

  10. Changes in body weight [ Time Frame: Measurement at 96 weeks ]
    body weight

  11. Changes in inflammatory markers [ Time Frame: Measurement at 96 weeks ]
    Ferritin in ng/mL

  12. Changes in inflammatory markers [ Time Frame: Measurement at 96 weeks ]
    C-rective protein (CRP) in mg/dL

  13. Changes in inflammatory markers [ Time Frame: Measurement at 96 weeks ]
    High sensitivity C-reactive protein (hs-CRP) in mg/L

  14. Changes in inflammatory markers [ Time Frame: Measurement at 96 weeks ]
    Interleukin 6 (IL-6) in pg/mL

  15. Changes in inflammatory markers [ Time Frame: Measurement at 96 weeks ]
    Interleukin 1 beta (IL-1b) in pg/mL

  16. Changes in inflammatory markers [ Time Frame: Measurement at 96 weeks ]
    Tumor necrosis factor alpha (TNFa) in pg/mL

  17. Changes in serum expression of incretins [ Time Frame: Measurement at 96 weeks ]
    serum expression of incretins

  18. Changes in mineral metabolism parameters. [ Time Frame: Measurement at 96 weeks ]
    Parathormone (PTH) (pg/mL), 25(OH)D (ng/mL), PINP, b-CTX (ng/mL)

  19. Changes in gut microbiota [ Time Frame: Measurement at 96 weeks ]
    Analysis using 16S rRNA sequencing from stool samples

  20. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Glucose in mg/dL

  21. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Hemoglobin A1c (HbA1c) in %

  22. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Homeostatic model assessment for insulin resistance (HOMA-IR) (not unit)

  23. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Adponectin in ug/mL

  24. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Retinol binding protein 4 (RBP-4) in ug/mL

  25. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Monocyte chemoattractant protein-1 (MCP-1) in ug/mL

  26. Changes in glucose homeostasis markers and insulin resistance [ Time Frame: Measurement at 96 weeks ]
    Plaminogen activator inhibitor-1 (PAI-1) in ug/mL

  27. Incidence of adverse events [ Time Frame: Measurement at 96 weeks ]
    Safety and tolerability



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subjects aged between 18 and 60 years (inclusive) at first screening visit.
  2. Must provide signed written informed consent and agree to comply with the study protocol.
  3. BMI between 35 and 45 kg/m2 with or without metabolic risk factors (type 2 diabetes, arterial hypertension, dyslipidaemia), and BMI between 30 and 34,9 kg/m2 with type 2 diabetes.
  4. Histological confirmation of steatohepatitis in a diagnostic liver biopsy (biopsy obtained in the 6 months prior to randomization or during the selection period) with at least a score of 1 in each component of the NAS score (steatosis with a score of 0 to 3, degeneration by ballooning with a score of 0 to 2 and lobular inflammation with a score of 0 to 3) and:

    • NAS score ≥ 4
    • fibrosis < 4 according to the staging system of CRN fibrosis on NASH
  5. For patients with fibrosis ≤ 1, must be associated at least one of the following conditions: metabolic syndrome (NCEP ATP III definition), type 2 diabetes, HOMA-IR >6
  6. Absence of other well documented causes of chronic liver disease (alcoholic liver disease, viral hepatitis, cholestasis, autoimmune hepatitis, Wilson's disease, hemochromatosis, alpha 1 antitrypsin deficiency)
  7. Patients agree to have 1 liver biopsy after 96 weeks after intervention

Exclusion Criteria:

  1. Known heart failure (Grade I to IV of the classification of the New York Heart Association).
  2. History of efficient bariatric surgery within 10 years prior to Screening.
  3. Patients with a history of clinically significant acute cardiac event in the 6 months prior to selection, such as: acute cardiovascular event, cerebrovascular accident, transient ischemic attack, or coronary heart disease (angina pectoris, myocardial infarction, revascularization procedures).
  4. Weight loss of more than 5% in the 6 months prior to randomization.
  5. Recent or current background of significant consumption of alcoholic beverages (<5 years). In the case of men, significant consumption is usually defined as more than 30 g of pure alcohol per day. In the case of women, it is usually defined as more than 20 g of pure alcohol per day.
  6. Liver cirrhosis.
  7. Non-cirrhotic portal hypertension.
  8. Esophagogastric varices.
  9. Hepatocellular carcinoma
  10. Portal thrombosis.
  11. Pregnancy.
  12. Refusal to give informed consent.
  13. Any medical condition that could reduce life expectancy to less than 2 years, including known cancers.
  14. Signs of any other unstable or clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease without treatment.
  15. Instability or mental incompetence, so that the validity of the informed consent or the ability to comply with the study are uncertain.
  16. Antibodies positive for the human immunodeficiency virus.
  17. Descompensated liver disease with the following hematologic and biochemical criteria:

    • Aspartate aminotransferase (AST) and / or ALT> 10 x upper limit of normal (ULN)
    • Total bilirubin> 25 μmol / l (1.5 mg / dl)
    • Standardized international index> 1.4
    • Platelet count <100 000 / mm3
  18. Serum creatinine levels> 135 μmol / l (> 1.53 mg / dl) in men and> 110 μmol / l (> 1.24 mg / dl) in women.
  19. Significant renal disease, including nephritic syndrome, chronic kidney disease (patients with markers of hepatic injury or estimated glomerular filtration rate [eGFR] of less than 60 ml / min / 1.73 m2). If an abnormal value is obtained at the first screening visit, the eGFR measurement may be repeated before randomization within the following time frame: minimum 4 weeks after the initial test and maximum 2 weeks before the expected randomization. An abnormal repeated eGFR (less than 60 ml / min / 1.73 m2) leads to exclusion from the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04060368


Contacts
Layout table for location contacts
Contact: Javier Crespo, PROF +34942204089 javier.crespo@scsalud.es
Contact: Paula Iruzubieta, MD, PhD +34942204089 p.iruzubieta@gmail.com

Locations
Layout table for location information
Spain
Hospitl Universitario Marqués de Valdecilla Recruiting
Santander, Cantabria, Spain, 39008
Contact: Paula Iruzubieta, PHD         
Sponsors and Collaborators
Instituto de Investigación Marqués de Valdecilla
Publications of Results:

Layout table for additonal information
Responsible Party: UECV, Dr. Javier Crespo, Instituto de Investigación Marqués de Valdecilla
ClinicalTrials.gov Identifier: NCT04060368    
Other Study ID Numbers: TESLA-NASH
First Posted: August 19, 2019    Key Record Dates
Last Update Posted: September 30, 2020
Last Verified: September 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by UECV, Instituto de Investigación Marqués de Valdecilla:
NASH
Obesity
Endoscopic Sleeve Gastroplasty
Laparoscopic Sleeve Gastrectomy
Additional relevant MeSH terms:
Layout table for MeSH terms
Fatty Liver
Non-alcoholic Fatty Liver Disease
Liver Diseases
Digestive System Diseases